Beta-catenin expression is prognostic of improved non-small cell lung cancer survival

American Journal of Surgery

Volumn 203, Issue 5, 2012, Pages 654-659

  Chiu, Connie G ^a   Chan, Simon K ^a   Fang, Z Amy ^a   Masoudi, Hamid ^a   Wood Baker, Richard ^a,b,c   Jones, Steven J M ^a   Gilks, Blake ^a   Laskin, Janessa ^b   Wiseman, Sam M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Beta catenin; Lung cancer; Molecular prognosticator; Non small cell lung cancer; Tissue microarray

Indexed keywords

BETA CATENIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; BIOSYNTHESIS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL;

AGED; BETA CATENIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 85058204940     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2012.01.002     Document Type: Article

References (24)

1. Solomon B, Bunn PA Jr. Adjuvant chemotherapy for non-small cell lung cancer. Cancer Invest 2007;25:217-25. (Pubitemid 47026945)
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in nonsmall cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
3. Vielh P, Spano JP, Grenier J, et al. Molecular prognostic factors in resectable non-small cell lung cancer. Crit Rev Oncol Hematol 2005; 53:193-7. (Pubitemid 40254918)
4. Zhu CQ, Shih W, Ling CH, et al. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790- 800.
5. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51(18 suppl):5054s-9s.
6. Mareel M, Berx G, Van Roy F, et al. Cadherin/catenin complex: a target for antiinvasive therapy? J Cell Biochem 1996;61:524 -30.
7. Pignatelli M, Vessey CJ. Adhesion molecules: novel molecular tools in tumor pathology. Hum Pathol 1994;25:849 -56.
8. Bremnes RM, Veve R, Hirsch FR, et al. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002;36:115-24. (Pubitemid 34302891)
9. Jiang WG. E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg 1996;83:437- 46.
10. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994;1198:11-26. (Pubitemid 24159061)
11. Renouf DJ, Wood-Baker R, Ionescu DN, et al. BCL-2 expression is prognostic for improved survival in non-small cell lung cancer. J Thorac Oncol 2009;4:486 -91.
12. Parker RL, Huntsman DG, Lesack DW, et al. Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. Am J Clin Pathol 2002;117:723- 8.
13. ACS Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society (Association of Caribbean States), 2008.
14. Hommura F, Furuuchi K, Yamazaki K, et al. Increased expression of beta-catenin predicts better prognosis in nonsmall cell lung carcinomas. Cancer 2002;94:752- 8.
15. Ramasami S, Kerr KM, Chapman AD, et al. Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol 2000;192:427-32.
16. Bremnes RM, Veve R, Gabrielson E, et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic signifi- cance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002;20:2417-28. (Pubitemid 34525727)
17. Kase S, Sugio K, Yamazaki K, et al. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000;6:4789 -96.
18. Lee YC, Wu CT, Chen CS, et al. The significance of E-cadherin and alpha-, beta-, and gamma-catenin expression in surgically treated nonsmall cell lung cancers of 3 cm or less in size. J Thorac Cardiovasc Surg 2002;123:502-7.
19. Papay J, Krenacs T, Moldvay J, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach. Appl Immunohistochem Mol Morphol 2007;15: 19 -30.
20. Retera JM, Leers MP, Sulzer MA, et al. The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. J Clin Pathol 1998;51:891- 4.
21. Nozawa N, Hashimoto S, Nakashima Y, et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract 2006;202:639 -50.
22. Iiizumi M, Liu W, Pai SK, et al. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 2008;1786:87-104.
23. Huber AH, Stewart DB, Laurents DV, et al. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem 2001;276: 12301-9.
24. Rao AS, Kremenevskaja N, von Wasielewski R, et al. Wnt/betacatenin signaling mediates antineoplastic effects of imatinib mesylate (Gleevec) in anaplastic thyroid cancer. J Clin Endocrinol Metab 2006; 91:159-68. (Pubitemid 43069132)